The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
Day-care model aimed at providing specialized psychological support for women during pregnancy and motherhood
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
